journal
MENU ▼
Read by QxMD icon Read
search

Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation

journal
https://read.qxmd.com/read/30775430/journal-club-endobronchial-valve-bronchoscopic-lung-volume-reduction
#1
Ron Balkissoon
No abstract text is available yet for this article.
January 25, 2019: Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
https://read.qxmd.com/read/30775429/the-copd-pipeline-xxxx
#2
Nicholas Gross
No abstract text is available yet for this article.
January 14, 2019: Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
https://read.qxmd.com/read/30775419/progress-in-alpha-1-antitrypsin-deficiency-collaboration-as-the-foundation-of-new-knowledge
#3
James K Stoller
No abstract text is available yet for this article.
January 14, 2019: Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
https://read.qxmd.com/read/30775425/mortality-and-exacerbations-by-global-initiative-for-chronic-obstructive-lung-disease-groups-abcd-2011-versus-2017-in-the-copdgene%C3%A2-cohort
#4
Rachel N Criner, Wassim W Labaki, Elizabeth A Regan, Jessica M Bon, Xavier Soler, Surya P Bhatt, Susan Murray, John E Hokanson, Edwin K Silverman, James D Crapo, Jeffrey L Curtis, Fernando J Martinez, Barry J Make, MeiLan K Han, Carlos H Martinez
Background: The Global initiative for chronic Obstructive Lung Disease (GOLD) ABCD groupings were recently modified. The GOLD 2011 guidelines defined increased risk as forced expiratory volume in 1 second (FEV1 ) < 50% predicted or ≥ 2 outpatient or ≥ 1 hospitalized exacerbation in the prior year, whereas the GOLD 2017 guidelines use only exacerbation history. We compared mortality and exacerbation rates in the Genetic Epidemiology of COPD Study cohort (COPDGene® ) by 2011 (exacerbation history/FEV1 and dyspnea) versus 2017 (exacerbations and dyspnea) classifications...
January 10, 2019: Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
https://read.qxmd.com/read/30775421/urban-rural-disparities-in-chronic-obstructive-pulmonary-disease-management-and-access-in-uganda
#5
Nicole M Robertson, Emily M Nagourney, Suzanne L Pollard, Trishul Siddharthan, Robert Kalyesubula, Pamela J Surkan, John R Hurst, William Checkley, Bruce J Kirenga
Introduction: Almost 90% of chronic obstructive pulmonary disease (COPD) deaths occur in low- and middle-income countries (LMICs), where there are large rural populations and access to health care for COPD is poor. The purpose of this study was to compare urban-rural provider experiences regarding systemic facilitators and barriers to COPD management and treatment access. Methods: We conducted a qualitative study using direct observations and in-depth semi-structured interviews with 16 and 10 health care providers in urban Kampala and rural Nakaseke, Uganda, respectively...
January 4, 2019: Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
https://read.qxmd.com/read/30775426/effects-of-roflumilast-on-rehospitalization-and-mortality-in-patients
#6
Gerard J Criner, Michael R Jacobs, Huaqing Zhao, Nathaniel Marchetti
Introduction: Hospitalization for chronic obstructive pulmonary disease (COPD) exacerbation portends the greatest risk of rehospitalization and mortality. Treatments that prevent hospitalizations could significantly lessen COPD morbidity and mortality. Methods: We performed a prospective, randomized, double-blind, placebo-controlled study of roflumilast 500 ug daily versus placebo in patients hospitalized for acute COPD exacerbation. Primary outcome was time to all-cause mortality or non-elective rehospitalization at 180 days post-randomization...
December 20, 2018: Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
https://read.qxmd.com/read/30775427/efficacy-and-safety-of-nebulized-glycopyrrolate-eflow%C3%A2-closed-system-in-patients-with-moderate-to-very-severe-chronic-obstructive-pulmonary-disease-with-pre-existing-cardiovascular-risk-factors
#7
Gary T Ferguson, Robert Tosiello, Shahin Sanjar, Thomas Goodin
Purpose: The purpose of this study was to assess the effect of pre-existing cardiovascular (CV) risk factors on the efficacy and safety of nebulized glycopyrrolate (GLY) in patients with chronic obstructive pulmonary disease (COPD). Methods: A total of 2379 patients from 3 phase III studies (12-week, placebo-controlled Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer [GOLDEN] -3 and -4, and 48-week, active-controlled GOLDEN-5) stratified by high (n=1526) or low (n=853) CV risk were randomized to placebo, GLY 25 mcg or 50 mcg twice daily, or tiotropium (TIO; 18 mcg once daily)...
December 13, 2018: Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
https://read.qxmd.com/read/30775424/patient-preferences-for-endobronchial-valve-treatment-of-severe-emphysema
#8
Carol Mansfield, Jessie Sutphin, Kelly Shriner, Gerard J Criner, Bartolome R Celli
Background: Patients with severe emphysema have limited treatment options. Little is known about patients' willingness to accept risks for new treatments that offer meaningful benefits. Methods: We determined treatment preferences of patients with severe emphysema using a web-based discrete-choice experiment survey. Respondents answered 9 questions that offered choices between 2 hypothetical interventional treatments or continuing current medical management. Variations in 5 attributes defined the 2 interventional treatments: improvement in ability to breathe and carry out day-to-day activities, frequency of hospitalized exacerbations, treatment type, risk of pneumothorax within 30 days of procedure, and risk of death within 3 months...
December 11, 2018: Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
https://read.qxmd.com/read/30775422/comparing-patients-with-zz-versus-sz-alpha-1-antitrypsin-deficiency-findings-from-alphanet-s-disease-management-program
#9
Radmila Choate, David M Mannino, Kristen E Holm, Robert A Sandhaus
Background : The aim of this study was to examine differences in demographic, health, and behavioral characteristics in individuals with ZZ and SZ genotypes of alpha-1 antitrypsin deficiency (AATD) within AlphaNet's Disease Management and Prevention Program (ADMAPP). Methods : Self-reported data from 3535 patients with AATD, including 3031 (85.7%) patients with ZZ, ZNull, and NullNull genotypes (referred to here as ZZ), and 504 (14.3%) with the SZ genotype were analyzed using t-tests, ANOVAs, and Chi-squared tests...
November 30, 2018: Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
https://read.qxmd.com/read/30775428/intravenous-alpha-1-antitrypsin-therapy-for-alpha-1-antitrypsin-deficiency-the-current-state-of-the-evidence
#10
REVIEW
Mark L Brantly, Jorge E Lascano, Abbas Shahmohammadi
Alpha-1 antitrypsin deficiency (AATD) is a largely monogenetic disorder associated with a high risk for the development of chronic obstructive pulmonary disease (COPD) and cirrhosis. Intravenous alpha-1 antitrypsin (AAT) therapy has been available for the treatment of individuals with AATD and COPD since the late 1980s. Initial Food and Drug Administration (FDA) approval was granted based on biochemical efficacy. Following its approval, the FDA, scientific community and third-party payers encouraged manufacturers of AAT therapy to determine its clinical efficacy...
November 28, 2018: Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
https://read.qxmd.com/read/30775420/costs-of-medical-care-among-augmentation-therapy-users-and-non-users-with-alpha-1-antitrypsin-deficiency-in-the-united-states
#11
Jan Sieluk, Joseph Levy, Robert A Sandhaus, Henry Silverman, Kristen E Holm, C Daniel Mullins
Background : This study is the first to utilize a large claims database to estimate medical costs of patients with alpha-1 antitrypsin deficiency (AATD) in the United States. Methods: Adult AATD patients were identified from the OptumLabs™ Data Warehouse. Insurer and patient out-of-pocket costs were categorized into the following cost buckets, stratified by augmentation therapy use: physician visits (PV), emergency department visits (ED), inpatient stays (IP), augmentation therapy (AUG), other prescription drug costs (RX), and other costs (OTH)...
November 8, 2018: Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
https://read.qxmd.com/read/30723791/journal-club-asthma-chronic-obstructive-pulmonary-disease-overlap-fact-or-fiction
#12
Ron Balkissoon
No abstract text is available yet for this article.
October 17, 2018: Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
https://read.qxmd.com/read/30723789/websites-online-communities-and-digital-channels-as-a-medium-to-effectively-educate-engage-and-empower-patients
#13
Elisha Malanga, Vincent Malanga, Sara Latham
No abstract text is available yet for this article.
October 17, 2018: Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
https://read.qxmd.com/read/30775423/effect-of-lung-volume-reduction-surgery-on-respiratory-muscle-strength-in-advanced-emphysema
#14
Rachel N Criner, Daohai Yu, Michael R Jacobs, Gerard J Criner
Background: Long-term effects of lung volume reduction surgery (LVRS) on respiratory muscle strength and effects of age, sex, and emphysema pattern on these changes are unknown. Therefore, we aimed to determine the long-term effect of LVRS on respiratory muscle strength changes in severe emphysema. Methods: The National Emphysema Treatment Trial was a prospective controlled multicentered trial, comparing LVRS to optimal medical treatment on survival and maximal exercise capacity. We examined percentage change in maximum inspiratory pressure (MIP) from baseline to 36 months follow-up to determine impact of LVRS as well as age, sex, emphysema pattern and exercise capacity on changes in MIP compared to medical treatment...
October 12, 2018: Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
https://read.qxmd.com/read/30723788/national-and-state-estimates-of-copd-morbidity-and-mortality-united-states-2014-2015
#15
Jamie Sullivan, Vira Pravosud, David M Mannino, Keith Siegel, Radmila Choate, Tracie Sullivan
Background: Chronic obstructive pulmonary disease (COPD) remains a leading cause of disability and death in the United States. The "COPD in the United States" project gathered data about the impact of COPD to highlight variability across states and provide a single point of access to data for state decision makers, the public health community and advocates. This report provides a summary of COPD-related morbidity and mortality in the United States and individual states during 2014-2015 (some metrics contain data from other years)...
October 12, 2018: Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
https://read.qxmd.com/read/30723780/why-publish-scientific-meeting-proceedings
#16
Adam Wanner
No abstract text is available yet for this article.
October 10, 2018: Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
https://read.qxmd.com/read/30723779/increasing-awareness-of-copd-two-steps-forward-one-step-back
#17
COMMENT
Kenneth R Chapman
No abstract text is available yet for this article.
October 9, 2018: Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
https://read.qxmd.com/read/30723785/antioxidants-and-chronic-obstructive-pulmonary-disease
#18
Félix-Antoine Vézina, André M Cantin
Antioxidants represent an attractive therapeutic avenue for individuals with chronic obstructive pulmonary disease (COPD). Cigarette smoke, the major cause of COPD, contains very high concentrations of gaseous and soluble oxidants that can directly induce cell injury and death. Furthermore, particulate matter in cigarette smoke activates lung macrophages that subsequently attract neutrophils. Both neutrophils and macrophages from the lungs of cigarette smokers continuously release large amounts of superoxide and hydrogen peroxide through the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex...
October 8, 2018: Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
https://read.qxmd.com/read/30723786/alpha-1-antitrypsin-therapy-for-autoimmune-disorders
#19
Sihong Song
Autoimmune diseases are conditions caused by an over reactive immune system that attacks self-tissues and organs. Although the pathogenesis of autoimmune disease is complex and multi-factorial, inflammation is commonly involved. Therefore, anti-inflammatory therapies hold potential for the treatment of autoimmune diseases. However, long-term control of inflammation is challenging and most of the currently used drugs have side effects. Alpha-1 antitrypsin (AAT) is an anti-inflammatory protein with a well-known safety profile...
October 5, 2018: Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
https://read.qxmd.com/read/30723787/3rd-world-bronchiectasis-conference
#20
Anne E O'Donnell, Timothy R Aksamit
No abstract text is available yet for this article.
October 2, 2018: Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
journal
journal
48953
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"